Neuronal and Cardiovascular Potassium Channels as Therapeutic Drug Targets: Promise and Pitfalls
Potassium (K+) channels, with their diversity, often tissue-defined distribution, and critical role in controlling cellular excitability, have long held promise of being important drug targets for the treatment of dysrhythmias in the heart and abnormal neuronal activity within the brain. With the ex...
Gespeichert in:
Veröffentlicht in: | Journal of Biomolecular Screening 2015-10, Vol.20 (9), p.1055-1073 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1073 |
---|---|
container_issue | 9 |
container_start_page | 1055 |
container_title | Journal of Biomolecular Screening |
container_volume | 20 |
creator | Humphries, Edward S. A. Dart, Caroline |
description | Potassium (K+) channels, with their diversity, often tissue-defined distribution, and critical role in controlling cellular excitability, have long held promise of being important drug targets for the treatment of dysrhythmias in the heart and abnormal neuronal activity within the brain. With the exception of drugs that target one particular class, ATP-sensitive K+ (KATP) channels, very few selective K+ channel activators or inhibitors are currently licensed for clinical use in cardiovascular and neurological disease. Here we review what a range of human genetic disorders have told us about the role of specific K+ channel subunits, explore the potential of activators and inhibitors of specific channel populations as a therapeutic strategy, and discuss possible reasons for the difficulty in designing clinically relevant K+ channel modulators. |
doi_str_mv | 10.1177/1087057115601677 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_crossref_primary_10_1177_1087057115601677</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1087057115601677</sage_id><sourcerecordid>1713944505</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-fa78f25e2ee80937ea508010e49d9a4def9c03e28e77dcc2deb677e68234cee53</originalsourceid><addsrcrecordid>eNp1UU1LxDAQDaL4ffckPXqpTpqkaS-CrN-IeljBWxjT6W6l26xJs-C_t8uqqOBpBt6b92beMHbA4ZhzrU84FBqU5lzlwHOt19g2VypLpZLP60M_wOkS32I7IbwCcJGD3GRbWS5ACNDb7Paeoncdtgl2VTJCXzVugcHGFn3y6HoMoYmzZDTFrqM2JBiS8ZQ8zin2jU3OfZwkY_QT6sMe26ixDbT_WXfZ0-XFeHSd3j1c3YzO7lIrhezTGnVRZ4oyogJKoQkVFMCBZFmVKCuqSwuCsoK0rqzNKnoZLqO8yIS0RErsstOV7jy-zKiy1PUeWzP3zQz9u3HYmN9I10zNxC2MVDpXoAeBo08B794ihd7MmmCpbbEjF4PhmotSSgVLL1hRrXcheKq_bTiY5QvM3xcMI4c_1_se-Mp8IKQrQsAJmVcX_RB_-F_wA92Lj88</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1713944505</pqid></control><display><type>article</type><title>Neuronal and Cardiovascular Potassium Channels as Therapeutic Drug Targets: Promise and Pitfalls</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Humphries, Edward S. A. ; Dart, Caroline</creator><creatorcontrib>Humphries, Edward S. A. ; Dart, Caroline</creatorcontrib><description>Potassium (K+) channels, with their diversity, often tissue-defined distribution, and critical role in controlling cellular excitability, have long held promise of being important drug targets for the treatment of dysrhythmias in the heart and abnormal neuronal activity within the brain. With the exception of drugs that target one particular class, ATP-sensitive K+ (KATP) channels, very few selective K+ channel activators or inhibitors are currently licensed for clinical use in cardiovascular and neurological disease. Here we review what a range of human genetic disorders have told us about the role of specific K+ channel subunits, explore the potential of activators and inhibitors of specific channel populations as a therapeutic strategy, and discuss possible reasons for the difficulty in designing clinically relevant K+ channel modulators.</description><identifier>ISSN: 1087-0571</identifier><identifier>ISSN: 2472-5552</identifier><identifier>EISSN: 1552-454X</identifier><identifier>DOI: 10.1177/1087057115601677</identifier><identifier>PMID: 26303307</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Animals ; Cardiovascular Agents - pharmacology ; Cardiovascular Agents - therapeutic use ; Cardiovascular Diseases - drug therapy ; Cardiovascular Diseases - metabolism ; Humans ; Myocardium - metabolism ; Nervous System Diseases - drug therapy ; Nervous System Diseases - metabolism ; Neurons - metabolism ; Potassium Channel Blockers - pharmacology ; Potassium Channel Blockers - therapeutic use ; Potassium Channels - physiology ; Review</subject><ispartof>Journal of Biomolecular Screening, 2015-10, Vol.20 (9), p.1055-1073</ispartof><rights>2015 Society for Laboratory Automation and Screening</rights><rights>2015 Society for Laboratory Automation and Screening.</rights><rights>2015 Society for Laboratory Automation and Screening 2015 Society for Laboratory Automation and Screening</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-fa78f25e2ee80937ea508010e49d9a4def9c03e28e77dcc2deb677e68234cee53</citedby><cites>FETCH-LOGICAL-c434t-fa78f25e2ee80937ea508010e49d9a4def9c03e28e77dcc2deb677e68234cee53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>313,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26303307$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Humphries, Edward S. A.</creatorcontrib><creatorcontrib>Dart, Caroline</creatorcontrib><title>Neuronal and Cardiovascular Potassium Channels as Therapeutic Drug Targets: Promise and Pitfalls</title><title>Journal of Biomolecular Screening</title><addtitle>J Biomol Screen</addtitle><description>Potassium (K+) channels, with their diversity, often tissue-defined distribution, and critical role in controlling cellular excitability, have long held promise of being important drug targets for the treatment of dysrhythmias in the heart and abnormal neuronal activity within the brain. With the exception of drugs that target one particular class, ATP-sensitive K+ (KATP) channels, very few selective K+ channel activators or inhibitors are currently licensed for clinical use in cardiovascular and neurological disease. Here we review what a range of human genetic disorders have told us about the role of specific K+ channel subunits, explore the potential of activators and inhibitors of specific channel populations as a therapeutic strategy, and discuss possible reasons for the difficulty in designing clinically relevant K+ channel modulators.</description><subject>Animals</subject><subject>Cardiovascular Agents - pharmacology</subject><subject>Cardiovascular Agents - therapeutic use</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Cardiovascular Diseases - metabolism</subject><subject>Humans</subject><subject>Myocardium - metabolism</subject><subject>Nervous System Diseases - drug therapy</subject><subject>Nervous System Diseases - metabolism</subject><subject>Neurons - metabolism</subject><subject>Potassium Channel Blockers - pharmacology</subject><subject>Potassium Channel Blockers - therapeutic use</subject><subject>Potassium Channels - physiology</subject><subject>Review</subject><issn>1087-0571</issn><issn>2472-5552</issn><issn>1552-454X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>EIF</sourceid><recordid>eNp1UU1LxDAQDaL4ffckPXqpTpqkaS-CrN-IeljBWxjT6W6l26xJs-C_t8uqqOBpBt6b92beMHbA4ZhzrU84FBqU5lzlwHOt19g2VypLpZLP60M_wOkS32I7IbwCcJGD3GRbWS5ACNDb7Paeoncdtgl2VTJCXzVugcHGFn3y6HoMoYmzZDTFrqM2JBiS8ZQ8zin2jU3OfZwkY_QT6sMe26ixDbT_WXfZ0-XFeHSd3j1c3YzO7lIrhezTGnVRZ4oyogJKoQkVFMCBZFmVKCuqSwuCsoK0rqzNKnoZLqO8yIS0RErsstOV7jy-zKiy1PUeWzP3zQz9u3HYmN9I10zNxC2MVDpXoAeBo08B794ihd7MmmCpbbEjF4PhmotSSgVLL1hRrXcheKq_bTiY5QvM3xcMI4c_1_se-Mp8IKQrQsAJmVcX_RB_-F_wA92Lj88</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Humphries, Edward S. A.</creator><creator>Dart, Caroline</creator><general>SAGE Publications</general><scope>AFRWT</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20151001</creationdate><title>Neuronal and Cardiovascular Potassium Channels as Therapeutic Drug Targets</title><author>Humphries, Edward S. A. ; Dart, Caroline</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-fa78f25e2ee80937ea508010e49d9a4def9c03e28e77dcc2deb677e68234cee53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Cardiovascular Agents - pharmacology</topic><topic>Cardiovascular Agents - therapeutic use</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Cardiovascular Diseases - metabolism</topic><topic>Humans</topic><topic>Myocardium - metabolism</topic><topic>Nervous System Diseases - drug therapy</topic><topic>Nervous System Diseases - metabolism</topic><topic>Neurons - metabolism</topic><topic>Potassium Channel Blockers - pharmacology</topic><topic>Potassium Channel Blockers - therapeutic use</topic><topic>Potassium Channels - physiology</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Humphries, Edward S. A.</creatorcontrib><creatorcontrib>Dart, Caroline</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Biomolecular Screening</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Humphries, Edward S. A.</au><au>Dart, Caroline</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neuronal and Cardiovascular Potassium Channels as Therapeutic Drug Targets: Promise and Pitfalls</atitle><jtitle>Journal of Biomolecular Screening</jtitle><addtitle>J Biomol Screen</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>20</volume><issue>9</issue><spage>1055</spage><epage>1073</epage><pages>1055-1073</pages><issn>1087-0571</issn><issn>2472-5552</issn><eissn>1552-454X</eissn><abstract>Potassium (K+) channels, with their diversity, often tissue-defined distribution, and critical role in controlling cellular excitability, have long held promise of being important drug targets for the treatment of dysrhythmias in the heart and abnormal neuronal activity within the brain. With the exception of drugs that target one particular class, ATP-sensitive K+ (KATP) channels, very few selective K+ channel activators or inhibitors are currently licensed for clinical use in cardiovascular and neurological disease. Here we review what a range of human genetic disorders have told us about the role of specific K+ channel subunits, explore the potential of activators and inhibitors of specific channel populations as a therapeutic strategy, and discuss possible reasons for the difficulty in designing clinically relevant K+ channel modulators.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>26303307</pmid><doi>10.1177/1087057115601677</doi><tpages>19</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1087-0571 |
ispartof | Journal of Biomolecular Screening, 2015-10, Vol.20 (9), p.1055-1073 |
issn | 1087-0571 2472-5552 1552-454X |
language | eng |
recordid | cdi_crossref_primary_10_1177_1087057115601677 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | Animals Cardiovascular Agents - pharmacology Cardiovascular Agents - therapeutic use Cardiovascular Diseases - drug therapy Cardiovascular Diseases - metabolism Humans Myocardium - metabolism Nervous System Diseases - drug therapy Nervous System Diseases - metabolism Neurons - metabolism Potassium Channel Blockers - pharmacology Potassium Channel Blockers - therapeutic use Potassium Channels - physiology Review |
title | Neuronal and Cardiovascular Potassium Channels as Therapeutic Drug Targets: Promise and Pitfalls |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T20%3A32%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neuronal%20and%20Cardiovascular%20Potassium%20Channels%20as%20Therapeutic%20Drug%20Targets:%20Promise%20and%20Pitfalls&rft.jtitle=Journal%20of%20Biomolecular%20Screening&rft.au=Humphries,%20Edward%20S.%20A.&rft.date=2015-10-01&rft.volume=20&rft.issue=9&rft.spage=1055&rft.epage=1073&rft.pages=1055-1073&rft.issn=1087-0571&rft.eissn=1552-454X&rft_id=info:doi/10.1177/1087057115601677&rft_dat=%3Cproquest_pubme%3E1713944505%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1713944505&rft_id=info:pmid/26303307&rft_sage_id=10.1177_1087057115601677&rfr_iscdi=true |